Mullegama Sureni V, Rosenfeld Jill A, Orellana Carmen, van Bon Bregje W M, Halbach Sara, Repnikova Elena A, Brick Lauren, Li Chumei, Dupuis Lucie, Rosello Monica, Aradhya Swaroop, Stavropoulos D James, Manickam Kandamurugu, Mitchell Elyse, Hodge Jennelle C, Talkowski Michael E, Gusella James F, Keller Kory, Zonana Jonathan, Schwartz Stuart, Pyatt Robert E, Waggoner Darrel J, Shaffer Lisa G, Lin Angela E, de Vries Bert B A, Mendoza-Londono Roberto, Elsea Sarah H
Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Signature Genomic Laboratories, PerkinElmer Inc., Spokane, WA, USA.
Eur J Hum Genet. 2014 Jan;22(1):57-63. doi: 10.1038/ejhg.2013.67. Epub 2013 May 1.
Copy number variations associated with abnormal gene dosage have an important role in the genetic etiology of many neurodevelopmental disorders, including intellectual disability (ID) and autism. We hypothesize that the chromosome 2q23.1 region encompassing MBD5 is a dosage-dependent region, wherein deletion or duplication results in altered gene dosage. We previously established the 2q23.1 microdeletion syndrome and report herein 23 individuals with 2q23.1 duplications, thus establishing a complementary duplication syndrome. The observed phenotype includes ID, language impairments, infantile hypotonia and gross motor delay, behavioral problems, autistic features, dysmorphic facial features (pinnae anomalies, arched eyebrows, prominent nose, small chin, thin upper lip), and minor digital anomalies (fifth finger clinodactyly and large broad first toe). The microduplication size varies among all cases and ranges from 68 kb to 53.7 Mb, encompassing a region that includes MBD5, an important factor in methylation patterning and epigenetic regulation. We previously reported that haploinsufficiency of MBD5 is the primary causal factor in 2q23.1 microdeletion syndrome and that mutations in MBD5 are associated with autism. In this study, we demonstrate that MBD5 is the only gene in common among all duplication cases and that overexpression of MBD5 is likely responsible for the core clinical features present in 2q23.1 microduplication syndrome. Phenotypic analyses suggest that 2q23.1 duplication results in a slightly less severe phenotype than the reciprocal deletion. The features associated with a deletion, mutation or duplication of MBD5 and the gene expression changes observed support MBD5 as a dosage-sensitive gene critical for normal development.
与异常基因剂量相关的拷贝数变异在包括智力残疾(ID)和自闭症在内的许多神经发育障碍的遗传病因中起着重要作用。我们假设包含MBD5的2q23.1染色体区域是一个剂量依赖性区域,其中缺失或重复会导致基因剂量改变。我们之前建立了2q23.1微缺失综合征,本文报告了23例2q23.1重复的个体,从而建立了一种互补的重复综合征。观察到的表型包括ID、语言障碍、婴儿期肌张力减退和粗大运动发育迟缓、行为问题、自闭症特征、面部畸形特征(耳廓异常、眉弓、突出的鼻子、小下巴、上唇薄)和轻微的手指异常(第五指弯曲和大而宽的第一趾)。所有病例的微重复大小各不相同,范围从68 kb到53.7 Mb,涵盖了一个包括MBD5的区域,MBD5是甲基化模式和表观遗传调控中的一个重要因素。我们之前报道,MBD5的单倍剂量不足是2q23.1微缺失综合征的主要病因,并且MBD5中的突变与自闭症有关。在本研究中,我们证明MBD5是所有重复病例中唯一共有的基因,并且MBD5的过表达可能是2q23.1微重复综合征中存在的核心临床特征的原因。表型分析表明,2q23.1重复导致的表型比相应的缺失略轻。与MBD5的缺失、突变或重复相关的特征以及观察到的基因表达变化支持MBD5是对正常发育至关重要的剂量敏感基因。